In a groundbreaking development, researchers at the University of Cambridge in the UK have unveiled a pioneering blood test that, when combined with an online psychiatric assessment, could significantly enhance the diagnosis of bipolar disorder.
According to a study published in JAMA Psychiatry, the blood test alone has the potential to diagnose up to 30 percent of individuals with bipolar disorder. However, its effectiveness is notably amplified when utilized alongside a digital mental health assessment.
This innovative approach holds promise in aiding physicians to distinguish between bipolar disorder and major depressive disorder, both of which presenA2t overlapping symptoms but require distinct pharmacological treatments.
While the blood test is currently in its proof-of-concept phase, the research team believes that it could serve as a valuable adjunct to existing psychiatric diagnostic procedures and contribute to a deeper understanding of the biological underpinnings of mental health conditions.
Bipolar disorder, affecting approximately one percent of the global population, translates to a staggering 80 million individuals worldwide. Alarmingly, nearly 40 percent of these patients receive misdiagnoses, often mistaken for major depressive disorder.
Study lead author Jakub Tomasik, from Cambridge’s Department of Chemical Engineering and Biotechnology, highlighted the diagnostic challenges faced by individuals with bipolar disorder, particularly due to their presentation of alternating periods of low mood and heightened manic episodes.
Acknowledging the significance of a comprehensive psychiatric assessment in accurate diagnosis, Tomasik underscored the prolonged waiting periods and time-consuming nature of these evaluations, emphasizing the need for expedited and accurate diagnostic protocols.
The research drew upon data and samples from the Delta study conducted between 2018 and 2020 in the UK, encompassing over 3,000 participants. Each participant underwent an extensive online mental health assessment comprising more than 600 questions, exploring various facets relevant to mental health disorders.
Out of these participants, approximately 1,000 individuals submitted dried blood samples obtained through a simple finger prick, subsequently analyzed for over 600 different metabolites using mass spectrometry.
After employing the Composite International Diagnostic Interview, a validated diagnostic tool for establishing mood disorder diagnoses, the study’s analysis included 241 participants. Notably, the researchers identified a significant biomarker signal for bipolar disorder, even after accounting for factors such as medication use.
The combined approach of patient-reported information and the biomarker test notably improved diagnostic accuracy, particularly for cases where the diagnosis was not initially apparent. Professor Sabine Bahn, who spearheaded the research, emphasized the complementary nature of the online assessment and the biomarker test, highlighting the importance of leveraging both methodologies for enhanced diagnostic precision.
Tomasik also underscored the preference of some patients for the biomarker test, lauding its objectivity and tangible results. As the research continues to pave the way for improved diagnostic tools and strategies, it holds the potential to revolutionize the landscape of mental health assessments and treatments worldwide.
Also Read: New Study Reveals Link Between Climate Reversal & Greenland Ice Sheet Stability
